Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Me...

Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)

Analysts fell to the sidelines weighing in on Conmed (CNMD) and Alkermes (ALKS) with neutral ratings, indicating that the experts are neither bulli...

Analysts’ Top Healthcare Picks: Conmed (CNMD), Alkermes (ALKS)

In a report released on July 10, Jason Gerberry from Bank of America Securities maintained a Sell rating on Alkermes, with a price target of $38.00...

Bank of America Securities Remains a Sell on Alkermes (ALKS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Immunome (IMNM) with bullish sen...

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Alkermes on July 7 and set a price target of $56.00. The company’s shares closed yes...

Alkermes (ALKS) Gets a Buy from RBC Capital

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNR...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)

Alkermes ( ($ALKS) ) has provided an announcement. On July 6, 2026, Alkermes and Amneal Pharmaceuticals terminated their Authorized Generic Product...

Alkermes Ends Generic VIVITROL Supply Agreement with Amneal

In a report released yesterday, Uy Ear from Mizuho Securities reiterated a Buy rating on Alkermes, with a price target of $65.00. According to TipR...

Alkermes (ALKS) Gets a Buy from Mizuho Securities

In a report released yesterday, Benjamin Burnett from Wells Fargo maintained a Buy rating on Alkermes, with a price target of $65.00. According to ...

Wells Fargo Keeps Their Buy Rating on Alkermes (ALKS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY), Stryker (SYK) and Alker...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Stryker (SYK) and Alkermes (ALKS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Butterfly Network (BFLY), Alkermes (ALKS) and Connec...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALKS	$52.72	+1.50%	1.71M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALKS	$52.72	+1.5%	1.71M
3
4
5
6

ALKS

ALKS

Get Alkermes plc Data in Excel

Get Alkermes plc Data in Excel